Findings

What do systematic reviews say?

311 questions · 323 findings · 30 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 47 · 14.6%GRADE not reported 21 · 6.5%Very low 91 · 28.2%Low 65 · 20.1%Moderate 82 · 25.4%High 17 · 5.3%

Atypical antipsychotics vs placebo

Responder status · treatment of disordered and problem gambling

Atypical antipsychotics showed no clear difference in responder status compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
RR 0.93 [0.62, 1.4]
1 study · 42 participants
Low

Summary of findings ‐ Typical antipsychotics vs placebo

Specific behaviour ‐ agitation

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Summary of findings ‐ Typical antipsychotics vs placebo

Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Summary of findings ‐ Typical antipsychotics vs placebo

Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Summary of findings ‐ Typical antipsychotics vs placebo

Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Summary of findings ‐ Typical antipsychotics vs placebo

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

Summary of findings ‐ Typical antipsychotics vs placebo

Somnolence

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Summary of findings ‐ Typical antipsychotics vs placebo

Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Atypical antipsychotics vs placebo

Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Atypical antipsychotics vs placebo

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Somnolence

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

Atypical antipsychotics vs placebo

Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Specific behaviour ‐ agitation

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Galantamine plus risperidone vs placebo plus risperidone

Stereotypical behaviours · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Intervention not reported

Typical antipsychotic vs placebo · critically ill adults with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 608 participants
High

Intervention not reported

Typical antipsychotics vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 515 participants
Moderate

Intervention not reported

Atypical antipsychotics vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 476 participants
Moderate

Intervention not reported

Typical antipsychotic vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 618 participants
Moderate